Unjoni Ewropea - Spanjol - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - agentes antineoplásicos - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Unjoni Ewropea - Spanjol - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinoma, pulmón no microcítico - agentes antineoplásicos - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Ekwador - Spanjol - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

takeda manufacturing austria ag [at] austria - 500 ui - polvo liofilizado y solvente para soluciÓn inyectable - cada ml contiene: actividad del desvío del inhibidor del factor viii???????25 u* *proteína total de la preparación 10 -30 mg

Ekwador - Spanjol - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

takeda ecuador cia. ltda. ecuador - vedolizumab 300 mg - polvo para concentrado para soluciÓn para perfusiÓn - cada vial contiene: vedolizumab 300 mg

Ekwador - Spanjol - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

takeda ecuador cia. ltda. ecuador - brentuximab vedotin 50 mg - polvo para concentrado para soluciÓn para perfusiÓn - cada vial contiene: brentuximab vedotin 50 mg

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

takeda pharmaceuticals international ag ireland branch - lantano - polvo oral - 1.000 mg - lantano 1000 mg - lantano, carbonato de

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

takeda pharmaceuticals international ag ireland branch - lantano carbonato - comprimido masticable - 500 mg - lantano carbonato 500 mg - lantano, carbonato de

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

takeda pharmaceuticals international ag ireland branch - lantano carbonato - comprimido masticable - 750 mg - lantano carbonato 750 mg - lantano, carbonato de

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

takeda pharmaceuticals international ag ireland branch - lantano - polvo oral - 750 mg - lantano 750 mg - lantano, carbonato de

Spanja - Spanjol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

takeda pharmaceuticals international ag ireland branch - lantano carbonato - comprimido masticable - 1.000 mg - lantano carbonato 1000 mg - lantano, carbonato de